Table 2.

Clinical characteristics of patients who developed pituitary-irAE

	Hypophysitis n=3	IAD n=13	P value
Malignancy			0.529
NSCLC	0	4 (30.8%)
MM	3 (100%)	9 (69.2%)
Age, years	59±11	67±10	0.251
Sex			0.509
Female	0	5 (38.5%)
Male	3 (100%)	8 (61.5%)
History of prior immunotherapy	2 (66.7%)	3 (23.1%)	0.214
Latest ICI			0.036
aCTLA-4 Ab	3 (100%)	3 (23.1%)
aPD-1 Ab	0	10 (76.9%)
Days to diagnosis from the first administration of the latest drug	56±27	162±108	0.008
No. of cases with enlarged pituitary by MRI	3 (100%)	0	0.002

Data are n (%) or mean±SD.

aCTLA-4 Ab, anti-cytotoxic T-lymphocyte antigen 4 antibodies; aPD-1 Ab, anti-programmed cell death-1 antibodies; IAD, isolated adrenocorticotropic hormone deficiency; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; MM, malignant melanoma; NSCLC, non-small cell lung carcinoma.